“
“Aims Cross-sectional evidence indicates that abdominal adiposity, hypertension, dyslipidaemia and glycaemia are associated with reduced metabolic clearance rate of insulin (MCRI). Little is

known about the progression of MCRI and whether components of metabolic syndrome are associated with the change in MCRI. In this study, we examined the association between components of metabolic syndrome and the 5-year change of MCRI. Methods At baseline and 5-year follow-up, we measured fasting plasma triglycerides (TG), high-density lipoprotein (HDL) cholesterol, blood pressure (BP), waist check details circumference (WC) and fasting blood glucose (FBG) in 784 non-diabetic find more participants in the Insulin Resistance Atherosclerosis Study. MCRI, insulin sensitivity (SI) and acute insulin response (AIR) were determined from frequently sampled intravenous glucose tolerance

tests. Results We observed a 29% decline of MCRI at follow-up. TG, systolic BP and WC at baseline were inversely associated with a decline of MCRI regression models adjusted for age, sex, ethnicity, smoking, alcohol consumption, energy expenditure, family history of diabetes, BMI, SI and AIR [=0.057 (95% confidence interval, CI: 0.11, 0.0084) for TG, =0.0019 (95% CI: 0.0035, 0.00023) for systolic BP and =0.0084 (95% CI: 0.013, 0.0039) for WC; all p<0.05]. Higher HDL cholesterol at baseline was associated with an increase in MCRI [multivariable-adjusted =0.0029 (95% CI: 0.0010,

0.0048), p=0.002]. FBG at baseline was not associated with MCRI at follow-up [multivariable-adjusted =0.0014 (95% CI: 0.0026, 0.0029)]. Conclusions MCRI declined progressively over 5years in a non-diabetic Bafilomycin A1 order cohort. Components of metabolic syndrome at baseline were associated with a significant change in MCRI.”
“Expert Rev. Anti Infect. Ther. 10(11), 1241-1247 (2012) Although the use of combination antiretroviral therapy has resulted in spectacular improvements in morbidity and mortality of HIV-1 infected patients, a need for the development of antiretroviral compounds with new mechanisms of action remains. Maraviroc (Celsentri (R); ViiV Healthcare, Middlesex, UK) is the only drug of the class of chemokine (C-C motif) receptor 5 antagonists registered for treatment for HIV-1-infected antiretroviral therapy-experienced patients. Registration was based on the MOTIVATE-1 and -2 studies, which compared the efficacy and tolerability of maraviroc in combination with optimized background therapy with placebo. The aim of this paper is to review the MOTIVATE studies and to discuss issues related to maraviroc therapy in clinical practice such as assessment of HIV-1 coreceptor tropism.